Octagon Capital Advisors’s Kymera Therapeutics KYMR Stock Holding History

Octagon Capital Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.5M	Sell	310,000 -115,000	-27%	-$9.88M	3.2%	10
2026 Q1	$35.4M	Sell	425,000 -110,000	-21%	-$8.71M	3.92%	8
2025 Q4	$41.6M	Buy	535,000 +175,000	+49%	+$11.8M	5.05%	6
2025 Q3	$20.4M	Buy	360,000 +94,000	+35%	+$4.24M	3.09%	12
2025 Q2	$11.6M	Buy	+266,000	New	+$9.16M	2.55%	19
2021 Q3	–	Sell	-100,000	Closed	-$4.85M	–	32
2021 Q2	$4.85M	Buy	+100,000	New	+$4.34M	1%	26

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Octagon Capital Advisors's KYMR Position: Q2 2026 in Review

Octagon Capital Advisors reduced its Kymera Therapeutics (KYMR) stake by 27% in Q2 2026, selling an estimated $9.88M and leaving 310,000 shares worth $35.5M. The position accounts for 3.2% of the portfolio, ranked #10.

Octagon Capital Advisors first reported a position in KYMR in Q2 2021 and has held it in 6 quarters since. The position peaked at $41.6M in Q4 2025. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Octagon Capital Advisors held 310,000 shares of Kymera Therapeutics worth $35.5M as of Q2 2026.
Octagon Capital Advisors sold 115,000 Kymera Therapeutics shares in Q2 2026, an estimated $9.88M.
Kymera Therapeutics made up 3.2% of Octagon Capital Advisors's portfolio in Q2 2026, its #10 holding.
Octagon Capital Advisors first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 6 quarters since.
Octagon Capital Advisors's Kymera Therapeutics position peaked at $41.6M in Q4 2025.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.